Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV
Direct-acting antivirals show promise for patients with liver cancer
This meta-analysis of 8,839 patients with hepatocellular carcinoma (HCC) and Hepatitis C virus infection found that direct-acting antivirals…
New data suggests that direct-acting antiviral drugs may improve survival and reduce cancer recurrence for people with Hepatitis C and liver…
Prophylactic PEG tube placement improves nutritional status and reduces hospitalizations for head and neck cancer patients
Proactive Feeding Tubes May Improve Support for Head and Neck Cancer
This meta-analysis of 1279 patients evaluates prophylactic versus reactive percutaneous endoscopic gastrostomy (PEG) tubes in head and neck …
Early placement of feeding tubes may improve nutritional stability and reduce hospital stays for patients undergoing head and neck cancer tr…
Late grade 2 or higher gastrointestinal toxicity is inversely associated with biochemical recurrence in prostate cancer
Gastrointestinal Toxicity Linked to Lower Prostate Cancer Recurrence Rates
This individual patient data meta-analysis of 6761 patients receiving conventional or moderately hypofractionated radiation therapy found th…
A large study found a link between certain side effects from radiation and lower rates of prostate cancer recurrence in over 6,700 patients.
Tamoxifen reduces distant recurrence risk by HR 0.37 in PR-positive postmenopausal breast cancer
Tamoxifen Shows Long Term Benefit for Specific Breast Cancer Types
This secondary analysis of a randomized controlled trial involving 559 postmenopausal patients with lymph node-negative, ER-positive/HER2-ne…
A 25-year follow up shows that tamoxifen may provide lasting protection against cancer recurrence for patients with specific hormone recepto…
FDA Approves Verzenio (abemaciclib) for Early and Advanced Breast Cancer
FDA approves Verzenio for early and advanced breast cancer.
FDA approved Verzenio (abemaciclib) for adjuvant treatment of HR+, HER2-, node-positive early breast cancer at high risk of recurrence, and …
The FDA approved Verzenio (abemaciclib) for two types of breast cancer: early stage with high risk of return, and advanced or metastatic dis…
FDA Approves Gleevec (imatinib) for Multiple Kinase-Driven Cancers
FDA approves Gleevec for several types of cancer and blood disorders.
FDA approved Gleevec (imatinib) for newly diagnosed Ph+ CML in chronic phase, Ph+ CML after interferon failure, Ph+ ALL, MDS/MPD, ASM, HES/C…
The FDA approved Gleevec (imatinib) for many cancers, including certain leukemias, stomach tumors, and skin cancer. This gives patients more…
Gut microbiome taxa and metabolites enhance immune checkpoint inhibitor efficacy and mitigate systemic toxicity
Gut bacteria may improve cancer treatment and reduce side effects
This systematic review examines the role of gut microbiota, including specific taxa like Bacteroides and Akkermansia muciniphila, in modulat…
Specific gut bacteria and their byproducts could help cancer treatments work better while protecting the heart and colon from inflammation.
FDA Approves Padcev (enfortumab vedotin) for Muscle Invasive Bladder Cancer
FDA approves Padcev combination for bladder cancer before and after surgery
FDA approved Padcev (enfortumab vedotin) in combination with pembrolizumab as neoadjuvant and adjuvant treatment for adult patients with mus…
The FDA approved Padcev with pembrolizumab for muscle invasive bladder cancer before and after surgery in patients who cannot take cisplatin…
Post-diagnosis physical activity of 7.5 MET-hr/week associated with lower all-cause mortality in prostate cancer
Higher physical activity linked to lower death rates in prostate cancer
This meta-analysis of 10 studies involving over 50,144 men with prostate cancer found that higher levels of post-diagnosis physical activity…
Men with prostate cancer who stay active after diagnosis may have a lower risk of death from all causes.
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
EUS-HGAS provides longer time to recurrent biliary obstruction than EUS-HGS in malignant biliary obstruction
New data shows specific stent placement lasts longer for bile blockages
This meta-analysis of individual patient data analyzed 451 patients with malignant biliary obstruction following failed ERCP. The analysis f…
A new analysis reveals that adding an antegrade stent can significantly delay the return of blocked bile flow in certain cancer patients.